


 Cite this: *RSC Adv.*, 2019, 9, 10486

Hyaluronic acid-mediated multifunctional iron oxide-based MRI nanoprobes for dynamic monitoring of pancreatic cancer†

 Yu Luo,^{‡b} Yuehua Li,^{‡c} Jing Li,^{‡c} Caixia Fu,^d Xiangrong Yu^{*e} and Li Wu^{*acf}

Regarded as the most promising technology for an early and precise detection of pancreatic cancer, a sensitive nanoprobe has been developed to enhance the accumulation of contrast agent at the tumor site. Hyaluronic acid (HA)-mediated multifunctional Fe₃O₄ nanoparticles (NPs) were used to target pancreatic cancer cells because on their cytomembrane they overexpress CD44, a receptor protein that has a high affinity to HA. The formation of HA-mediated multifunctional Fe₃O₄ nanoparticles began with the synthesis of polyethyleneimine (PEI·NH₂) stabled Fe₃O₄ NPs by slight reduction. Subsequently, the formed Fe₃O₄@PEI·NH₂ NPs were modified with fluorescein isothiocyanate (FITC), polyethylene glycol (mPEG-COOH) and HA in succession to form the multifunctional Fe₃O₄ NPs denoted as HA-Fe₃O₄ NPs. HA served as a targeting molecule to identify the surface antibody of CD44. As nanoparticles with a diameter of ca. 11.9 nm, the HA-Fe₃O₄ NPs exhibited very high *r*₂ relaxivity of 321.4 mM⁻¹ s⁻¹ and this has proved that HA-Fe₃O₄ NPs could be efficient T₂-weighted magnetic resonance imaging (MRI) contrast agents. In a CCK8 cell proliferation assay of HA-Fe₃O₄ NPs, there was no toxic response for Fe concentrations up to 100 μg mL⁻¹. Flow cytometry, confocal microscopy observation, and cell MRI results show that the HA-targeted groups had significantly higher cellular uptake than the nontargeted groups. This demonstrates that the HA-Fe₃O₄ NPs are uptaken by pancreatic cells *via* an HA-mediated targeting pathway. The HA-mediated active targeting strategy could be applied to other biomedical projects.

Received 28th January 2019

Accepted 19th March 2019

DOI: 10.1039/c9ra00730j

rsc.li/rsc-advances

Introduction

Pancreatic cancer is a relatively common cancer with a 5 year survival rate of less than 8%.¹ The optimal treatment prolonging the patients lives with pancreatic cancer is radical surgery. However, metastasis has frequently begun during diagnosis, and the resection rate is less than 20%. For the survival of the patient, earlier detection and diagnosis of pancreatic cancer is particularly important.

Magnetic resonance imaging (MRI) is considered an effective method for the diagnosis of pancreatic cancer because of its high resolution and noninvasive imaging mode.² In one examination, with the use of safer intravenous contrast agents, MRI can perform noninvasive assessments of the pancreatic parenchyma, vascular network, and neighboring soft tissues. MR contrast agents are divided into two major categories: T₁ and T₂ MR contrast agents based on gadolinium and superparamagnetic iron oxide nanoparticles (Fe₃O₄ NPs).^{3–7} Currently, gadolinium-based contrast agents (GBCAS) are used in clinical applications of MRI.^{8,9} However, severe complications associated with GBCAS are increasing as they are being linked with nephrogenic systemic fibrosis (NSF).¹⁰ Fe₃O₄ NPs provide several advantages compared to traditional T₁ contrast agents by having a higher magnetic signal intensity, longer contrast enhancement, and in particular, lower cytotoxicity.¹¹ However, there are two main limitations to using Fe₃O₄ NPs as MR contrast agents. Firstly, they were engulfed by macrophage and gathered in the reticuloendothelial system (RES).¹² The passive targeting of cancer is due to the differences between the tumor and normal tissue with respect to their number of blood vessels, the wider gap in the vascular wall and poor structural integrity in solid tumor tissue, resulting in, enhanced permeability and retention (EPR) effect of tumor blood vessel.^{13,14} The EPR effect

^aInstitute of Biomedical Manufacturing and Life Quality Engineering, School of Mechanical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, P. R. China. E-mail: fdw1525@163.com

^bSchool of Chemical Science and Engineering, Tongji University, 1239 Siping Road, Shanghai 200092, P. R. China

^cInstitute of Diagnostic and Interventional Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China

^dMR Application Development, Siemens Shenzhen Magnetic Resonance Ltd, Shenzhen, China

^eDepartment of Radiology, Zhuhai Hospital of Jinan University, Zhuhai People's Hospital, 79 Kangning Road, Zhuhai, Guangdong 519000, P. R. China

^fDepartment of Pediatrics, University of Washington, Seattle, USA

† Electronic supplementary information (ESI) available: Part of experimental details and additional experimental results. See DOI: 10.1039/c9ra00730j

‡ Yu Luo, Yuehua Li, and Jing Li contributed equally to this work.



difference is minor between pancreatic cancer tissues and normal pancreatic tissue. Also, the tumor can show hyperintensity or isointensity in the contrast-enhanced MRI. In addition, during the early stage of lesions, tumors are smaller and more difficult to detect. Nanoprobes that are modified with specific ligand molecules to target delivery to the tumor site are essential for highly sensitive MRI of pancreatic tumors.¹⁵

Recent studies have shown that CD44, a protein that has an important part in the aggressive pancreatic cancer, is overexpressed in pancreatic cancer cell lines.^{13,16–19} CD44 is a receptor with a high affinity for HA and contributes to cellular processes such as cell survival, differentiation, proliferation, adhesion, migration, and chemo-resistance.^{20–23} Studies have shown that HA has been an effective ligand for targeting therapy for pancreatic cancer.^{24,25} However, there are few reports using CD44 as a target for diagnosis of pancreatic cancer with MR.

In this study, multifunctional HA modified Fe₃O₄ NPs were developed by covalently modifying synthesized Fe₃O₄-PEI NPs with HA, fluorescein isothiocyanate (FITC), and mPEG *via* a PEI-mediated conjugation chemistry strategy. The final product was denoted as HA-Fe₃O₄ NPs (Scheme 1). Fe₃O₄ NPs modified with multifunctional HA were applied for MRI of MIAPaca-2 cells, a CD44 overexpressing cancer cell line, and orthotopic transplantation model. The *in vivo* MRI was performed to monitor the growth of the tumor. This study provides the experimental basis for increased accuracy and observation of the development of pancreatic tumors *via* the targeting MRI-guidance strategy and could have enormous potential application in earlier detection of pancreatic cancer.

Experimental

Preparation of Fe₃O₄-PEI·NH₂

The method of Fe₃O₄-PEI NPs synthesis is as follows.²⁶ Argon gas was pumped into FeCl₃·6H₂O solution (2.6 g/40 mL) to remove oxygen for 30 minutes under intense stirring before sodium sulfite solution (0.4 g/20 mL) added with the same time. The reaction mixture was transferred to a 500 mL three-necked flask and a PEI·NH₂ solution (1.0 g/10 mL) was then added to the flask. After mixing, heated the flask up to 60–70 °C for 30 min, cooled it to room temperature and continued stirring for about 2 h. The mixture was separated and purified by an external magnetic field, and the same steps were repeated three to five times with water. Finally, the obtained Fe₃O₄ were redissolved in water (25 mL) and stored at 4 °C for further use.

Synthesis of FITC labeled Fe₃O₄ NPs

The Fe₃O₄ nanoparticles (120 mg) prepared in the last step were dispersed in 20 mL. FITC (4.2 mg, 1 mL in DMSO) solution was added to the suspension of Fe₃O₄ nanoparticles to avoid light and stirred vigorously at ambient temperature for one day. After that, the FITC labeled Fe₃O₄ NPs were fabricated.

Synthesis of HA-Fe₃O₄ NPs


The polyethylene glycol modification method was adopted to improve the colloid stability and biocompatibility of Fe₃O₄ NPs. Firstly, dissolved Fe₃O₄ NPs (60 mg) into 5 mL DMSO, activated the carboxyl group of mPEG-COOH with EDC (1.7 mg) and NHS (1.5 mg) for 3 h. The solution was added to FITC-labeled Fe₃O₄ suspension by dropwise manner, the reaction lasted for 3 days and avoid light. The reaction products were divided into two equal parts. And one part of the solution was added triethylamine (187.5 μL) and acetic anhydride (200 μL) respectively to form the non-HA materials (denoted as non-HA targeted control group materials: nHA-Fe₃O₄ NP). Another part of the solution was respectively added with triethylamine (75 μL) and acetic anhydride (80 μL) to obtain the partially acetylated iron oxide nanoparticles. 116 mg of hyaluronic acid was weighed and dissolved in 5 mL water. Then, adopted the similar carboxyl activation method of mPEG-COOH to active the -COOH of hyaluronic acid (EDC 1.3 mg for 30 min and then added NHS 1.1 mg for 3 h). After that, the solution was added to the partially acetylated iron oxide nanoparticles and continued reaction 3 days to form the multifunctional iron oxide nanoparticles modified by hyaluronic acid. The formed multifunctional iron oxide particles (denoted as HA-Fe₃O₄ NPs) were then collected after removing excess reactants and by-products *via* separation and purification. Finally, the NPs was released into water (5 mL) and stored at 4 °C.

Cytotoxicity testing and cell morphology observation

MIAPa-Ca-2 cells were cultivated by the similar manner of our previous report.¹⁰ After being treated with nHA-Fe₃O₄ NPs or HA-Fe₃O₄ NPs, the morphology, and cell viability were observed under microscopy (Leica DMIL LED inverted phase contrast microscope) and measured by the CCK-8 assay.

MR imaging *in vivo*

All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of Shanghai Jiao Tong University and experiments were approved by the Animal Ethics Committee of Shanghai Jiao Tong University. The



Scheme 1 Synthesis Routes of the HA-Fe₃O₄ NPs.






Fig. 1 TEM image of nHA-Fe₃O₄ NPs (a) and HA-Fe₃O₄ NPs (b), respectively.

management of animals and the establishment of *in situ* pancreatic cancer tumors model are similar to our previous work.²⁷ Scanning was performed at 7, 14 and 21 days after the operation on a 3.0 tesla MR (MAGNETOM Verio, Siemens) with a mouse coil.

Results and discussion

Preparation of HA-Fe₃O₄ NPs

The morphology and size of the synthesized nHA and HA-Fe₃O₄ NPs were determined by using TEM (Fig. 1). They were clearly seen that there was a uniform size distribution for particles with an approximate circular morphology. The nHA and HA-Fe₃O₄ NPs were measured to have a mean diameter of 12.2 ± 1.7 nm (Fig. 1a) and 11.9 ± 1.9 nm (Fig. 1b) respectively. Table S1 (ESI[†]) showed the hydrodynamic sizes and zeta potentials of the Fe₃O₄-PEI, nHA and HA-Fe₃O₄ NPs. With respect to zeta potentials, Fe₃O₄-PEI, due to the abundance of amino groups, had a zeta potential of +32.1 mV while the zeta potentials of the nHA-Fe₃O₄ and HA-Fe₃O₄ NPs decrease to +12.2 and -16.6 mV. The hydrodynamic size of Fe₃O₄-PEI, nHA-Fe₃O₄, and HA-Fe₃O₄ NPs are 240.9 nm, 289.3 nm, and 306.1 nm, respectively. The size difference between the various types of NPs showed that the

surface modification was successful. The colloid stability of nHA-Fe₃O₄ and HA-Fe₃O₄ NPs were one of the core premises for the further biologic application. It is found that after dispersing in water for 7 days, the hydrodynamic sizes of nHA-Fe₃O₄ and HA-




Fig. 2 Thermogravimetric analysis of Fe₃O₄-PEI NPs (black curve), nHA-Fe₃O₄ NPs (red curve), and HA-Fe₃O₄ NPs (blue curve), respectively.






Fig. 3 T₂ MR image and r_2 relaxivity of the nHA-Fe₃O₄ NP or HA-Fe₃O₄ NPs as a function of Fe concentration.

Fe₃O₄ NPs changed slightly, but without visible aggregations or precipitations (Fig. S1 and S2, ESI[†]) indicating, that the prepared NPs were colloidal stable. The characteristic absorption peak at 520 nm of FITC was observed in the HA-Fe₃O₄ NPs (Fig. S3, ESI[†]) thus, the UV-Vis results indicated that FITC had been successfully conjugated with HA-Fe₃O₄ NPs.

The percentage of HA in the Fe₃O₄ NPs was analyzed quantitatively by using TGA (Fig. 2). The weight of PEI and HA in the Fe₃O₄ NPs was measured to be 9.8% and 5.7% respectively, further indicating there was a successful surface modification of FITC-mPEG and HA. The curve of room temperature magnetic performance confirms the nHA-Fe₃O₄ or HA-Fe₃O₄ NPs presents obvious superparamagnetism, and the saturation magnetization of nHA-Fe₃O₄ or HA-Fe₃O₄ NPs is calculated to be 90.5 emu g⁻¹ and 101.3 emu g⁻¹, respectively (Fig. S4, ESI[†]).

T₂ relaxivity measurements

The relaxation times of nHA-Fe₃O₄ and HA-Fe₃O₄ NPs were quantified on a 0.5 T NMI20 Analysing and Imaging System to examine the feasibility of these NPs as a T₂-weighted MR contrast agent (Shanghai NIUMAG Corporation, Shanghai, China). Fig. 3 contains the T₂-weighted MR images that showed decreasing MRI signal intensity with increasing Fe concentrations in both the nHA-Fe₃O₄ and HA-Fe₃O₄ NPs (Fig. 3a). The r_2 of the nHA and HA-Fe₃O₄ NPs were counted. As shown in Fig. 3b, the r_2 of nHA-Fe₃O₄ and HA-Fe₃O₄ NPs were counted to be 204.1 and 321.4 mM⁻¹ s⁻¹. The high r_2 of nHA-Fe₃O₄ and HA-Fe₃O₄ NPs indicated that these NPs can be used as potential T₂ weighted contrast agents for MRI.

Cell morphology and cytotoxicity assay observation

The cytotoxicity of nHA-Fe₃O₄ and HA-Fe₃O₄ NPs were tested before MR scanning. After the MIAPaCa-2 cells were cultivated for 24 hours with nHA-Fe₃O₄ and HA-Fe₃O₄ NPs at particle concentrations of 10, 20, 60, 80 and 100 μg mL⁻¹, the cell viability was assessed by the CCK8 assay (Fig. 4). When compared with a PBS control, the viability of MIAPaCa-2 cells had no significant influence after incubation with either nHA-Fe₃O₄ or HA-Fe₃O₄ NPs within the tested concentration range (10–100 μg mL⁻¹). The results indicated that both particles were no cytotoxicity at the given concentration.

The cytocompatibility of the nHA-Fe₃O₄ or HA-Fe₃O₄ NPs were further explored by observed the morphology of MIAPaCa-2 cells treated with the NPs (Fig. S5, ESI[†]). The MIAPaCa-2 cells did not show any morphological changes at the studied Fe concentrations when compared with the PBS control. Both the morphological and CCK8 data was consistent further validating that both nHA-Fe₃O₄ and HA-Fe₃O₄ NPs had a good cytocompatibility.

Cellular uptake

The conjugation of FI moiety and Fe₃O₄ NPs was necessary to observe the cellular uptake of the nHA and HA-Fe₃O₄ NPs by confocal microscopy and flow cytometry assay. The mean fluorescence intensity between the two NPs treatments was compared (Fig. 5 and S6, ESI[†]). MIAPaCa-2 cells incubated with




Fig. 4 The viability of MIAPaCa-2 cells after treated with PBS, nHA-Fe₃O₄ NP and HA-Fe₃O₄ NPs at the different Fe concentrations for 24 h (A) or 48 h (B) at 37 °C by the CCK-8 assay.






Fig. 5 The ability of MIAPaCa-2 cells to uptake PBS (a), nHA-Fe₃O₄ NP (b) and HA-Fe₃O₄ NPs (c) ([Fe] 50 μg mL⁻¹) 4 hours after treatment, MIAPaCa-2 cells treated with PBS were used as control, scale bar = 10 μm.

HA-Fe₃O₄ NPs showed the fluorescence intensity higher than that with nHA-Fe₃O₄ NPs as the Fe concentration was increased. The ligand–receptor interaction between CD44 and HA ligands should be related to the improved cellular uptake of the HA-Fe₃O₄ NPs by MIAPaCa-2 cells.

Nuclei appeared blue when MIAPaCa-2 cells were added with PBS (Fig. 5a). When MIAPaCa-2 cells treated with either nHA or HA-Fe₃O₄ NPs at a Fe concentration of 60 μg mL⁻¹, they displayed intense green fluorescent signals that originated from FI on the cell surfaces and in the cytosol (Fig. 5b and c). However, the cells treated with HA-Fe₃O₄ NPs had an increased number of cells displaying a green fluorescence. This indicated that the HA-Fe₃O₄ NPs were uptaken by MIAPaCa-2 cells by active targeting pathway.

Prussian blue staining was applied to qualitatively assess the specific cellular uptake of the HA-Fe₃O₄ NPs by MIAPaCa-2 (Fig. S7, ESI[†]). The MIAPaCa-2 cells that were treated with the HA-Fe₃O₄ NPs displayed significantly deep blue staining than cells treated with the nHA-Fe₃O₄ NPs with the same Fe concentrations. Blue staining was not displayed in control cells added with PBS. The flow cytometry assay (Fig. 6), confocal microscopy observation results, and the Prussian blue staining results demonstrated the function of HA-mediated targeting.

In vitro MRI of cancer cells

The nHA and HA-Fe₃O₄ NPs were used as probes for MR scanning of MIAPaCa-2 cells. Before MR scanning, MIAPaCa-2 cells

overexpressing CD44 receptor were incubated with nHA-Fe₃O₄ or HA-Fe₃O₄ NPs at a range of Fe concentrations from 5 to 80 μg mL⁻¹ at 37 °C and 5% CO₂ for 4 hours. T₂ WI of the cells were collected (Fig. 7).

It was showed in cells treated with both nHA-Fe₃O₄ and HA-Fe₃O₄ NPs that the MR signal intensity decreased with Fe





Fig. 6 Flow cytometric analysis of the MIAPaCa-2 cells treated with the nHA-Fe₃O₄ NP or HA-Fe₃O₄ NPs for 4 h at the different Fe concentration.






Fig. 7 *In vitro* T₂ MR images of MIPaCa-2 cells treated with the nHA-Fe₃O₄ NP or HA-Fe₃O₄ NPs for 4 h.

concentration increasing. This further demonstrates that by attaching the HA ligand, the NPs could be directly targeting to cells.

MRI of tumor in mice

The nHA-Fe₃O₄ NPs or HA-Fe₃O₄ NPs were injected intravenously into mice (0.3 mL in PBS, 0.6 mg Fe per mouse) for MR scanning at 7, 14 and 21 days after tumor seeding (Fig. 8). After the HA-Fe₃O₄ NPs were injected, the MR signal of tumor gradually decreased (Fig. 8b, d and 8f). The highest contrast enhancement was induced by the particles at 90 min post-injection while the MR signal started to recover at 180 min. Compare to HA-Fe₃O₄ NPs, the tumor MR signal injected with nHA-Fe₃O₄ NPs did not decrease during the post-injection (Fig. 8a, c and e). It was well known that the decreased MR signal of tumor after injection with nHA-Fe₃O₄ NPs was associated with the EPR effect. Results showed that the HA-directed targeting role enabled specific

delivery of the particles to the tumor, thus, in conjunction with the passive EPR effect, there was specific MRI of the tumor. The MR signal intensity of tumors injected with both nHA-Fe₃O₄ and HA-Fe₃O₄ NPs were recovered to some extent at 180 min post-injection. Likely, the NPs have undergone the metabolism process decreased distribution in the tumor. At 7, 14 and 21 days after tumor seeding, there was a gradual decrease in MR signal intensity with the tumor.

21 days after tumor seeding, MR scanning was performed, then, the mice were sacrificed and the tumors were removed for HE staining (Fig. S8 and S9, ESI[†]). Microscopically, the tumor cells were spindle-shaped and had large nuclei with visible nucleoli. The nuclear fission of the tumor cells was inconspicuous at 7 and 14 days after tumor seeding. The tumor cells invade the surrounding acinar tissue and destroy the acinar forming a single acinar like “island” at 21 days after tumor seeding. The brown refractive particles were seen in tumor interstitial tissue during this period. The quantity of particles in




Fig. 8 *In vivo* transverse T₂ MR images of tumors after intravenous injection of the nHA-Fe₃O₄ NP ((a) 7 days; (c) 14 days; (e) 21 days) and HA-Fe₃O₄ NPs ((b) 7 days; (d) 14 days; (f) 21 days) ([Fe] 1 mg mL⁻¹, in 200 µL saline) at different time points post i.v.-injection.






Fig. 9 *In vivo* biodistribution of hearts, livers, spleens, lungs, kidneys, and tumors 24 h post intravenous injection of the nHA-Fe₃O₄ NP and HA-Fe₃O₄ NPs (600 μg Fe, in 0.3 mL PBS).

HA-Fe₃O₄ NPs group is significantly higher than that nHA-Fe₃O₄ NPs group. Given the different time points, the results may suggest that HA-Fe₃O₄ NPs can early detect a pancreatic tumor as contrast agent, especially compared to nHA-Fe₃O₄ NPs.

In vivo biodistribution and acute toxicity assessment

ICP-AES was used to analyze the Fe concentration in main organs to further observe the biodistribution behavior of the nHA and HA-Fe₃O₄ NPs (Fig. 9). 24 hours after the injection of nHA-Fe₃O₄ or HA-Fe₃O₄ NPs, the Fe concentration in tumor tissue and tested organs increased more than that of the control mice. Fe was uptaken mainly by the liver and spleen. However, a small quantity remains in the hearts, lungs, kidneys, and tumors. The Fe gather in the liver and spleen were closely related to the clearance effect of RES. The biological acute toxicity assessment was performed by the routine blood-biochemical blood testing (Fig. S10, ESI†). The nHA-Fe₃O₄ or HA-Fe₃O₄ NPs saline solution was intravenously injected into mice at a dosage (40 mg kg⁻¹). Afterward, mice were sacrificed 10 days post-injection (*n* = 10). Healthy mice with age and weight matched were the control group. The liver and kidney function indexes including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AKP), blood urea nitrogen (BUN) and creatinine (CREA) appeared normal. The blood indexes had no significant differences between the treatment groups and the control group.

Conclusions

In this study, we developed an HA-Fe₃O₄ NPs for targeted MRI of pancreatic cancer. These Fe₃O₄ NPs were proved to be stable, water soluble, and cytocompatible in the given concentration set. The results of cellular uptake analysis indicated that the HA-Fe₃O₄ NPs were specifically uptaken by MIApCa-2 cells which overexpress the CD44 receptor. In summary, as effective nanoparticles for MRI of pancreatic cancer cells and an orthotopic pancreatic cancer model through the HA-mediated active

targeting pathway, the developed HA-Fe₃O₄ NPs will play a great role as MR contrast agent for early detection of pancreatic cancer.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the Medical and Technology Intercrossing Research Foundation of Shanghai Jiaotong University (YG2014QN07) and the National Natural Science Foundation of China (Grant No. 51602334). The authors would like to thank Thomas Derezes for making significant edits to the manuscript and Pathologist Fuqiang Wang for interpretation to the tumor HE staining.

Notes and references

- P. L. S. Uson Junior, D. Callegaro-Filho, D. D. G. Bugano, F. Moura and F. C. Maluf, *J. Gastrointest. Cancer*, 2018, **49**, 481–486.
- C. Multari, M. Miola, S. Ferraris, D. Movia, K. Z. Rozman, N. Kostevsek, A. Follenzi, E. Verne and A. Prina-Mello, *Int. J. Appl. Ceram. Technol.*, 2018, **15**, 947–960.
- J. Li, L. Zheng, H. Cai, W. Sun, M. Shen, G. Zhang and X. Shi, *Biomaterials*, 2013, **34**, 8382–8392.
- S. Wen, K. Li, H. Cai, Q. Chen, M. Shen, Y. Huang, C. Peng, W. Hou, M. Zhu and G. Zhang, *Biomaterials*, 2013, **34**, 1570–1580.
- C. Guo, L. Sun, H. Cai, Z. Duan, S. Zhang, Q. Gong, K. Luo and Z. Gu, *J. Gastrointest. Cancer*, 2017, **9**, 23508–23519.
- Q. Luo, X. Xiao, X. Dai, Z. Duan, D. Pan, H. Zhu, X. Li, L. Sun, K. Luo and Q. Gong, *J. Gastrointest. Cancer*, 2018, **10**, 1575–1588.
- C. Hao, X. Wang, Z. Hu, S. Ling, D. Pan, Q. Gong, Z. Gu and K. Luo, *Appl. Mater. Today*, 2018, **11**, 207–218.
- Y. Luo, J. Yang, J. Li, Z. Yu, G. Zhang, X. Shi and M. Shen, *Colloids Surf., B*, 2015, **136**, 506–513.
- Y. Luo, L. Zhao, X. Li, J. Yang, L. Guo, G. Zhang, M. Shen, J. Zhao and X. Shi, *J. Mater. Chem. B*, 2016, **4**, 7220–7225.
- Y. Luo, J. Yang, Y. Yan, J. Li, M. Shen, G. Zhang, S. Mignani and X. Shi, *Nanoscale*, 2015, **7**, 14538–14546.
- C. Zhang, Y. Yan, Q. Zou, J. Chen and C. Li, *Asia-Pac. J. Clin. Onco.*, 2016, **12**, 13–21.
- J. Li, Y. He, W. Sun, Y. Luo, H. Cai, Y. Pan, M. Shen, J. Xia and X. Shi, *Biomaterials*, 2014, **35**, 3666–3677.
- B. B. S. Cerqueira, A. Lasham, A. N. Shelling and R. Al-Kassas, *Eur. J. Pharm. Biopharm.*, 2015, **97**, 140–151.
- S. Sharifi, H. Seyednejad, S. Laurent, F. Atyabi, A. A. Saei and M. Mahmoudi, *Contrast Media Mol. Imaging*, 2015, **10**, 329–355.
- J. Xie, K. Chen, H. Y. Lee, C. Xu, A. R. Hsu, S. Peng, X. Chen and S. Sun, *J. Am. Chem. Soc.*, 2008, **130**, 7542–7543.
- S. Zhao, C. Chen, K. Chang, A. Karnad, J. Jagirdar, A. P. Kumar and J. W. Freeman, *Clin. Cancer Res.*, 2016, **22**, 5592–5604.



- 17 J. Wei, Y. Zhang, K. T. Kane, M. A. Collins, D. M. Simeone, M. P. D. Magliano and K. T. Nguyen, *Mol. Cancer Res.*, 2015, **13**, 9–15.
- 18 N. J. Wood, *Nat. Rev. Gastroenterol. Hepatol.*, 2014, **11**, 427–428.
- 19 M. Kumazoe, M. Takai, J. Bae, S. Hiroi, Y. Huang, K. Takamatsu, Y. Won, M. Yamashita, S. Hidaka and S. Yamashita, *Oncogene*, 2016, **36**, 2643.
- 20 K. H. Bae, J. J. Yoon and T. G. Park, *Biotechnol. Prog.*, 2006, **22**, 297–302.
- 21 G. Jiang, K. Park, J. Kim, K. S. Kim, E. J. Oh, H. Kang, S. E. Han, Y. K. Oh, T. G. Park and H. S. Kwang, *Biopolymers*, 2010, **89**, 635–642.
- 22 M. Kamat, K. Elboubbou, D. C. Zhu, T. Lansdell, X. Lu, W. Li and X. Huang, *Bioconjugate Chem.*, 2015, **21**, 2128–2135.
- 23 S. Kiuchi, S. Ikeshita, Y. Miyatake and M. Kasahara, *Exp. Mol. Pathol.*, 2015, **98**, 41–46.
- 24 P. Kesharwani, S. Banerjee, S. Padhye, F. H. Sarkar and A. K. Iyer, *Biomacromolecules*, 2015, **16**, 3042–3053.
- 25 X. P. Li, X. W. Zhang, L. Z. Zheng and W. J. Guo, *Int. J. Clin. Exp. Pathol.*, 2015, **8**, 6724–6731.
- 26 Y. Hu, J. Li, J. Yang, P. Wei, Y. Luo, L. Ding, W. Sun, G. Zhang, X. Shi and M. Shen, *Biomater. Sci.*, 2015, **3**, 721–732.
- 27 L. Wu, P. Lv, H. Zhang, C. Fu, X. Yao, C. Wang, M. Zeng, Y. Li and X. Wang, *Magn. Reson. Imaging*, 2015, **33**, 737–760.

